上海弘升科技發展有限公司

上海弘升科技發展有限公司
上海弘升科技發展有限公司

当前位置:弘升科技 > 公司简介

测量应用案例-20210205

2021-02-24 14:23:20

419

文献名: LongCirculating DrugDyeBased Micelles with Ultrahigh pHSensitivity for Deep Tumor Penetration and Superior ChemoPhotothermal Therapy


上海弘升科技發展有限公司 Cunfeng Song ;Yugang Li ;Tianliang Li ;Yuming Yang ;Zhicheng Huang ;Jesús Martinez de la Fuente ;Jian Ni ;Daxiang Cui

Institute of Nano Biomedicine and Engineering ,Shanghai Engineering Research Center for Intelligent Instrument for Diagnosis and Therapy ,Department of Instrument Science & Engineering

School of Electronic Information and Electrical Engineering ,Shanghai Jiao Tong University,

800 Dongchuan Road, Shanghai 200240, P. R. China

 

摘要:Nanocarriers for chemophotothermal therapy suffer from insufficient retention at the tumor site and poor penetration into tumor parenchyma. A smart drugdyebased micelle is designed by making the best of the structural features of smallmolecule drugs. PDOX is synthesized by conjugating doxorubicin (DOX) with poly(4formylphenyl methacrylateco2(diethylamino) ethyl methacrylate)bpolyoligoethyleneglycol methacrylate (P(FPMAcoDEA)bPOEGMA) via imine linkage. Through the π–π stacking interaction, IR780, a nearinfrared fluorescence dye as well as a photothermal agent, is integrated into the micelles (IR780PDMs) with the PDOX. The IR780PDMs show remarkably long blood circulation (t1/2β = 22.6 h). As a result, a progressive tumor accumulation and retention are presented, which is significant to the sequential drug release. Moreover, when entering into a moderate acidic tumor microenvironment, IR780PDMs can dissociate into smallsize conjugates and IR780, which obviously increases the penetration depth of drugs, and then improves the lethality to deepseated tumor cells. Owing to the high delivery efficiency and superior chemophotothermal therapeutic efficacy of IR780PDMs, 97.6% tumor growth in the A549 tumorbearing mice is suppressed with a low dose of intravenous injection (DOX, 1.5 mg kg1; IR780, 0.8 mg kg1). This work presents a brandnew strategy for longacting intensive cancer therapy.


分享到微信朋友圈

分享到其他

010-51627740

上海弘升科技發展有限公司 上海弘升科技發展有限公司
上海弘升科技發展有限公司